Synendos Therapeutics expands Series A round
Synendos Therapeutics, a biopharmaceutical company focused on treating central nervous system disorders, has expanded its Series A round to CHF 24 million.
Synendos Therapeutics, a biopharmaceutical company focused on treating central nervous system disorders, has expanded its Series A round to CHF 24 million.
Copyright PEI Media
Not for publication, email or dissemination